Friday 12 August, 0730 - 0815

Abbot Logo.jpg
Life changing technologies

Synopsis: The 2 topics to feature are Coronary Mircovascular Disease and Mitral Regurgitation

AMGEN logo.jpg
Lipid Management in Acute Coronary Syndrome (ACS)

Speaker: Prof Peter Psaltis, SAHMRI, Adelaide and Dr Adam Nelson, Victorian Heart Institute, Monash University, Melbourne

Synopsis: Lipid management in ACS with a focus on the benefits of early and aggressive, in-hospital initiation of lipid-lowering therapy post-MI.


Guideline-recommended treatment options for SGLT2i in HFrEF in clinical practice- What should we do?

Speaker: Prof Andrew Coates & A/Prof John Amerena

Chair: Dr Scott Mackenzie

Synopsis: There has never been a more exciting time or opportunity to optimise treatment interventions and improve patient outcomes in HFrEF. Join Prof. Andrew Coates and A/Prof. John Amerena in this interactive symposium, chaired by Dr Scott Mackenzie, to discuss the change in treatment paradigm for HFrEF, challenges in implementation and role of SGLT2i in the management of HFrEF.

Innovative Medical Device Technology Solutions in Complex Coronary and Structural Intervention

Chair: Dr Sidney Lo

Speakers: Dr Scott Harding (New Zealand), Dr Pratap Shetty (NSW), Dr Sanjeevan Pasupati (New Zealand) and Dr Rustem Dautov (QLD)

Synopsis: Understand how latest innovative medical device technologies can solve clinical challenges in complex coronary and structural heart procedures. We will discuss a coronary drug-eluting stent for diabetics, an atherectomy device which provides effective plaque modification for calcified coronary lesions, and a novel bicaval valve implantation device for tricuspid regurgitation.

BI - Lilly Logos combined (1).png
Australian and International HFrEF Guidelines: key changes, similarities and differences – who’s right?

 Synopsis: Over the last 12-18 months, we have seen significant changes to Heart Failure guidelines all around the world, particularly in the area of Heart Failure with Reduced Ejection Fraction (HFrEF). With the new Universal Heart Failure classification as well as the introduction of SGLT2is as a new pillar of standard of care, there have been significant changes to the recommendation on how we diagnose and manage our patients. There are significant similarities across HF guidelines around the world, but also some key differences. Who has the best approach? What are the key things for us to focus on in Australia when managing and treating our patients? When should we be initiating therapy and in what order? In-hospital initiation vs initiation in the outpatient/private setting? How soon after a hospitalisation should therapy be introduced? This symposium aims to review guideline directed medical therapy, highlighting the differences and consistencies across local and international guidelines with a view to reviewing the benefits of these for our patients. 

medtronic logo.jpg

Leadless Pacing Innovation

Speaker: Russell Denman

The Great Cholesterol Debate 

Synopsis: The debate will explore the association of lipoprotein(a) in atherosclerotic CVD and how low to go with LDL-C

Sanofi update.jpg
The link between influenza and cardiovascular disease: rollout of a pilot influenza vaccination programme in the cardiology setting

Speakers: Prof Timothy Tan & Dr Sarah Monagle

Synopsis: There is also a growing body of evidence that vaccination against influenza may reduce your risk of developing cardiovascular diseases related to influenza complications, however influenza vaccination screening for cardiovascular patients is not routinely undertaken within the hospital setting.
Herein we discuss a pilot rollout in the implementation of an influenza vaccination protocol for patients hospitalised with cardiovascular conditions and how this has affected practice.


Friday 12 August, 1250 - 1350

medtronic logo.jpg

TAVI Durability: Important considerations for lifetime management

Speaker: Dr Michael J. Reardon

Panellists: Prof Darren Walters (QLD) and A/Prof Tony Walton (VIC)

Synopsis: With Michael Reardon and guests, we discuss the salient points of a Low Risk patient. Guidance from experts on patient selection, heart team meetings, lifetime management plans and the importance of haemodynamics in these younger patients. Join us as we unpack one of the largest changes to TAVI this decade. 


Unleashing the potential benefits of Entresto as part of guideline-directed heart failure treatments

Chair: Prof Andrew Coats

Speakers: A/Prof John Amerena & Dr Nicole Bart

Talks: Can we change the outlook for patients with HFrEF? & Optimising Entresto for hospitalised HF patients: what, when and how? 


Saturday 7 August, 1220 - 1320

BI - Lilly Logos combined (1).png

HFpEF diagnosis and patient pathways of care ... are we there yet?

Chair: Heart Failure with Preserved Ejection Fraction is a condition that requires specific diagnostic pathways and a very specific management approach and with relatively less awareness as a disease and its diagnosis compared to other types of Heart Failure. In addition, there is a lack of clear guidelines on diagnosis and no clear treatment guidelines or universally accepted management approach. More needs to be done to develop clear and accepted HFpEF patient pathways with the quality of echo reporting and its standardisation a significant opportunity for improvement. This symposium aims to improve the understanding of the pathophysiology, diagnosis and prognosis of HFpEF in Australia and will explore approaches both here and around the world to highlight gaps in diagnosis and referral pathways while identifying areas of focus to improve future patient care and quality of life.